Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial

Crit Care. 2018 Aug 17;22(1):193. doi: 10.1186/s13054-018-2124-8.

Abstract

Background: Low cardiac output syndrome (LCOS) is a severe condition which can occur after cardiac surgery, especially among patients with pre-existing left ventricular dysfunction. Dobutamine, its first-line treatment, is associated with sinus tachycardia. This study aims to assess the ability of intravenous ivabradine to decrease sinus tachycardia associated with dobutamine infused for LCOS after coronary artery bypass graft (CABG) surgery.

Methods: In a phase 2, multi-center, single-blind, randomized controlled trial, patients with left ventricular ejection fraction below 40% presenting sinus tachycardia of at least 100 beats per minute (bpm) following dobutamine infusion for LCOS after CABG surgery received either intravenous ivabradine or placebo (three ivabradine for one placebo). Treatment lasted until dobutamine weaning or up to 48 h. The primary endpoint was the proportion of patients achieving a heart rate (HR) in the 80- to 90-bpm range. Secondary endpoints were invasive and non-invasive hemodynamic parameters and arrhythmia events.

Results: Nineteen patients were included. More patients reached the primary endpoint in the ivabradine than in the placebo group (13 (93%) versus 2 (40%); P = 0.04). Median times to reach target HR were 1.0 h in the ivabradine group and 5.7 h in the placebo group. Ivabradine decreased HR (112 to 86 bpm, P <0.001) while increasing cardiac index (P = 0.02), stroke volume (P <0.001), and systolic blood pressure (P = 0.03). In the placebo group, these parameters remained unchanged from baseline. In the ivabradine group, five patients (36%) developed atrial fibrillation (AF) and one (7%) was discontinued for sustained AF; two (14%) were discontinued for bradycardia.

Conclusion: Intravenous ivabradine achieved effective and rapid correction of sinus tachycardia in patients who received dobutamine for LCOS after CABG surgery. Simultaneously, stroke volume and systolic blood pressure increased, suggesting a beneficial effect of this treatment on tissue perfusion.

Trial registration: European Clinical Trials Database: EudraCT 2009-018175-14 . Registered February 2, 2010.

Keywords: Cardiac surgery; Cardiogenic shock; Coronary artery bypass graft; Dobutamine; Low cardiac output syndrome; Postoperative atrial fibrillation; Sinus tachycardia; Systolic heart failure.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Aged
  • Cardiac Output, Low / etiology*
  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Agents / therapeutic use
  • Coronary Artery Bypass / adverse effects*
  • Coronary Artery Bypass / methods
  • Dobutamine / therapeutic use
  • Elective Surgical Procedures / adverse effects
  • Elective Surgical Procedures / methods
  • Female
  • Humans
  • Ivabradine / therapeutic use*
  • Male
  • Middle Aged
  • Placebos / therapeutic use
  • Single-Blind Method

Substances

  • Cardiotonic Agents
  • Cardiovascular Agents
  • Placebos
  • Ivabradine
  • Dobutamine